{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:33:35Z","timestamp":1791027215782,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T00:00:00Z","timestamp":1364256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJOG"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Previous studies have provided conflicting results regarding the effect of drospirenone\u2010containing oral contraceptive pills (\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      s) on the risk of venous and arterial thrombosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To conduct a systematic review to assess the risk of venous thromboembolism (\n                      <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n                      ), myocardial infarction (\n                      <jats:styled-content style=\"fixed-case\">MI<\/jats:styled-content>\n                      ), and stroke in individuals taking drospirenone\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      s.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Search strategy<\/jats:title>\n                    <jats:p>\n                      We systematically searched\n                      <jats:styled-content style=\"fixed-case\">CINAHL<\/jats:styled-content>\n                      , the Cochrane Library, Dissertation &amp; Abstracts,\n                      <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>\n                      , HealthStar, Medline, and the Science Citation Index from inception to November 2012.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Selection criteria<\/jats:title>\n                    <jats:p>\n                      We included all case reports, observational studies, and experimental studies assessing the risk of venous and arterial thrombosis of drospirenone\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      s.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data collection and analysis<\/jats:title>\n                    <jats:p>Data were collected independently by two reviewers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main results<\/jats:title>\n                    <jats:p>\n                      A total of 22 studies [six case reports, three case series (including 26 cases), and 13 comparative studies] were included in our systematic review. The 32 identified cases suggest a possible link between drospirenone\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      s and venous and arterial thrombosis. Incidence rates of\n                      <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n                      among drospirenone\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      users ranged from 23.0 to 136.7 per 100\u00a0000 woman\u2010years, whereas those among levonorgestrel\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      users ranged from 6.64 to 92.1 per 100\u00a0000 woman\u2010years. The rate ratio for\n                      <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n                      among drospirenone\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      users ranged from 4.0 to 6.3 compared with non\u2010users of\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      s, and from 1.0 to 3.3 compared with levonorgestrel\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      users. The arterial effects of drospirenone\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      s were inconclusive.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Author's conclusions<\/jats:title>\n                    <jats:p>\n                      Our systematic review suggests that drospirenone\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      use is associated with a higher risk for\n                      <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n                      than both no\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      use and levonorgestrel\u2010containing\n                      <jats:styled-content style=\"fixed-case\">OCP<\/jats:styled-content>\n                      use.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/1471-0528.12210","type":"journal-article","created":{"date-parts":[[2013,3,26]],"date-time":"2013-03-26T11:24:42Z","timestamp":1364297082000},"page":"801-811","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Drospirenone\u2010containing oral contraceptive pills and the risk of venous and arterial thrombosis: a systematic review"],"prefix":"10.1111","volume":"120","author":[{"given":"CQ","family":"Wu","sequence":"first","affiliation":[{"name":"Faculty of Medicine McGill University Montreal QC Canada"},{"name":"Center for Clinical Epidemiology Lady Davis Institute for Medical Research Jewish General Hospital Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SM","family":"Grandi","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology Lady Davis Institute for Medical Research Jewish General Hospital Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KB","family":"Filion","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology Lady Davis Institute for Medical Research Jewish General Hospital Montreal QC Canada"},{"name":"Division of Clinical Epidemiology McGill University Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HA","family":"Abenhaim","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology Lady Davis Institute for Medical Research Jewish General Hospital Montreal QC Canada"},{"name":"Department of Obstetrics and Gynecology Jewish General Hospital Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Joseph","sequence":"additional","affiliation":[{"name":"Division of Clinical Epidemiology McGill University Health Center Montreal QC Canada"},{"name":"Department of Epidemiology, Biostatistics, and Occupational Health McGill University Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MJ","family":"Eisenberg","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology Lady Davis Institute for Medical Research Jewish General Hospital Montreal QC Canada"},{"name":"Division of Cardiology Jewish General Hospital\/McGill University Montreal QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2010.01.045"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003216"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105173442007"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp030751"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029607302445"},{"key":"e_1_2_7_7_1","first-page":"721","article-title":"YAZ and the novel progestin drospirenone","volume":"53","author":"Mishell DR","year":"2008","journal-title":"J Reprod Med"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2139"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d2151"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1783\/147118910791749416"},{"key":"e_1_2_7_11_1","unstructured":"FDA Advisory Committee Joint Meeting: Reproductive Health Drugs; Drug Safety and Risk Management.2011[www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/ReproductiveHealthDrugsAdvisoryCommittee\/UCM284784.pdf]. Accessed 12 January 2012."},{"key":"e_1_2_7_12_1","unstructured":"FDA Drug Safety Communication: Updated information about the FDA\u2010funded study on risk of blood clots in women taking birth control pills containing drospirenone.2011[www.fda.gov\/Drugs\/DrugSafety\/ucm299305.htm]. Accessed 30 December 2011."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7383.257"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/CH-2009-1190","article-title":"Yasmin and venous thromboembolism: new case reports","volume":"42","author":"Lopez M","year":"2009","journal-title":"Clin Hemorheol Microcirc"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3181b0c965"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02373.x"},{"key":"e_1_2_7_19_1","first-page":"254","article-title":"Update on combined oral contraceptives: risk of venous thromboembolism. Drospirenone versus other progestins","volume":"19","author":"Marti Gil C","year":"2012","journal-title":"Eur J Hosp Pharm"},{"key":"e_1_2_7_20_1","first-page":"80","article-title":"Myocardial infarction in a young female smoker taking oral contraception. Infarctus du myocarde chez une jeune femme fumeuse sous contraception orale","volume":"99","author":"Cabou C","year":"2006","journal-title":"Arch Mal Coeur Vaiss"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e3283467fc9"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2003.10.019"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6423"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.110463"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.12.019"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2890"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000279448.62221.a8"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/jfprhc-2012-100297"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2921"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111840"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.01.006"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-7824(97)00119-4"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwg231"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61745-0"},{"key":"e_1_2_7_35_1","unstructured":"Yasmin: risk of venous thromboembolism higher than levonorgestrel\u2010containing pills.2011[www.mhra.gov.uk\/Safetyinformation\/DrugSafetyUpdate\/CON120214]. Accessed 30 December 2011."},{"key":"e_1_2_7_36_1","unstructured":"Yasmin and Yaz (drospirenone): Updated information on increased risk of blood clots.2011[www.hc-sc.gc.ca\/ahc-asc\/media\/advisories-avis\/_2011\/2011_164-eng.php]. Accessed 30 December 2011."},{"key":"e_1_2_7_37_1","unstructured":"FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone.2012[www.fda.gov\/Drugs\/DrugSafety\/ucm299305.htm]. Accessed 14 May 2012."},{"key":"e_1_2_7_38_1","first-page":"191","article-title":"Oral contraceptives and venous thromboembolism: a systematic review and meta\u2010analysis","volume":"35","author":"Manzoli L","year":"2012","journal-title":"Drug Saf"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3109\/13625187.2011.643836"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0412.1997.tb07855.x"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427130-00003"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/jfprhc-2011-100260"}],"container-title":["BJOG: An International Journal of Obstetrics &amp; Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1471-0528.12210","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1471-0528.12210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:17:48Z","timestamp":1700630268000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/1471-0528.12210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,26]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/1471-0528.12210"],"URL":"https:\/\/doi.org\/10.1111\/1471-0528.12210","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717995567.793474661","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717995567.793475241","asserted-by":"object"}]},"ISSN":["1470-0328","1471-0528"],"issn-type":[{"value":"1470-0328","type":"print"},{"value":"1471-0528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,26]]},"assertion":[{"value":"2013-01-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-03-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}